LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Hoang, Linda"
  2. AU="Richard W G Caldow"
  3. AU="Marina, Ljiljana"
  4. AU="Fu, Jingde" AU="Fu, Jingde"
  5. AU="Zhang, Eunice J"
  6. AU="Shidong Lv"
  7. AU=Sydow M
  8. AU="Fernandez-Guzmán, Daniel"
  9. AU="Jarc, Erika"
  10. AU="Vincent Assey"
  11. AU="Taylor, Marisa"
  12. AU="Shanto, Hasibul Hasan"
  13. AU="Ahmad Khanshour"

Suchergebnis

Treffer 1 - 10 von insgesamt 177

Suchoptionen

  1. Artikel ; Online: Rapid, high-throughput, cost-effective whole-genome sequencing of SARS-CoV-2 using a condensed library preparation of the Illumina DNA Prep kit.

    Hickman, Rebecca / Nguyen, Jason / Lee, Tracy D / Tyson, John R / Azana, Robert / Tsang, Frankie / Hoang, Linda / Prystajecky, Natalie A

    Journal of clinical microbiology

    2024  Band 62, Heft 3, Seite(n) e0010322

    Abstract: The ongoing COVID-19 pandemic necessitates cost-effective, high-throughput, and timely whole-genome sequencing (WGS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses for outbreak investigations, identifying variants of concern (VoC) ...

    Abstract The ongoing COVID-19 pandemic necessitates cost-effective, high-throughput, and timely whole-genome sequencing (WGS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses for outbreak investigations, identifying variants of concern (VoC), characterizing vaccine breakthrough infections, and public health surveillance. In addition, the enormous demand for WGS on supply chains and the resulting shortages of laboratory supplies necessitated the use of low-reagent and low-consumable methods. Here, we report an optimized library preparation method (the BCCDC cutdown method) that can be used in a high-throughput scenario, where one technologist can perform 576 library preparations (6 plates of 96 samples) over the course of one 8-hour shift. The same protocol can also be used in a rapid turnaround time scenario, from primary samples (up to 96 samples) to loading on a sequencer in an 8-hour shift. This new method uses Freed et al.'s 1,200 bp primer sets (Biol Methods Protoc 5:bpaa014, 2020, https://doi.org/10.1093/biomethods/bpaa014) and a modified and condensed Illumina DNA Prep workflow (Illumina, CA, USA). Compared to the original protocol, the application of this new method using hundreds of clinical specimens demonstrated equivalent results to the full-length DNA Prep workflow at 45% of the cost, 15% of consumables required (such as pipet tips), 25% of manual hands-on time, and 15% of on-instrument time if performing on a liquid handler, with no compromise in sequence quality. Results demonstrate that this new method is a rapid, simple, cost-effective, and high-quality SARS-CoV-2 WGS protocol.
    Importance: Sequencing has played an invaluable role in the response to the COVID-19 pandemic. Ongoing work in this area, however, demands optimization of laboratory workflow to increase sequencing capacity, improve turnaround time, and reduce cost without compromising sequence quality. This report describes an optimized DNA library preparation method for improved whole-genome sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. The workflow advantages summarized here include significant time, cost, and consumable savings, which suggest that this new method is an efficient, scalable, and pragmatic alternative for SARS-CoV-2 whole-genome sequencing.
    Mesh-Begriff(e) Humans ; SARS-CoV-2 ; COVID-19 ; Cost-Benefit Analysis ; Pandemics ; Gene Library ; DNA ; High-Throughput Nucleotide Sequencing/methods
    Chemische Substanzen DNA (9007-49-2)
    Sprache Englisch
    Erscheinungsdatum 2024-02-05
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/jcm.00103-22
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: Escherichia coli

    Smith, Courtney / Griffiths, Allison / Allison, Sandra / Hoyano, Dee / Hoang, Linda

    Canada communicable disease report = Releve des maladies transmissibles au Canada

    2022  Band 48, Heft 1, Seite(n) 46–50

    Abstract: Background: In April 2021, a Shiga toxin-producing : Methods: Confirmed cases of : Results: Six confirmed cases of : Conclusion: Raw vegetables, such as celery, are a potential source of STEC and present a risk to vulnerable populations. ... ...

    Abstract Background: In April 2021, a Shiga toxin-producing
    Methods: Confirmed cases of
    Results: Six confirmed cases of
    Conclusion: Raw vegetables, such as celery, are a potential source of STEC and present a risk to vulnerable populations. Recommendations from this outbreak include more frequent testing at the processor, a review of the chlorination and mincing process and a review of hospital food services practices to mitigate temperature abuse.
    Sprache Englisch
    Erscheinungsdatum 2022-01-26
    Erscheinungsland Canada
    Dokumenttyp Journal Article
    ZDB-ID 1146585-2
    ISSN 1188-4169
    ISSN 1188-4169
    DOI 10.14745/ccdr.v48i01a07
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada

    Vadlamudi, Nirma K / Patrick, David M / Rose, Caren / Sadatsafavi, Mohsen / Hoang, Linda / Marra, Fawziah

    Vaccine. 2022 Feb. 11, v. 40, no. 7

    2022  

    Abstract: Pneumonia is a leading cause of morbidity and mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on community-acquired pneumonia (CAP) rates eight years after the vaccine was introduced in the infant ... ...

    Abstract Pneumonia is a leading cause of morbidity and mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on community-acquired pneumonia (CAP) rates eight years after the vaccine was introduced in the infant immunization program. Using diagnostic codes from administrative databases, we calculated the overall and age-specific CAP incidence per month (2000–2018). Changes in the CAP incidence before and after the PCV13 vaccine program introduction were evaluated using negative binomial regression model adjusting for 7-valent pneumococcal conjugate vaccine program. The PCV13 vaccine infant immunization program was associated with declining CAP incidence among children aged 0–2 years (adjusted Incidence Rate Ratio (aIRR): 0.91; 95% CI: 0.87–0.96). Overall CAP incidence did not decrease in those aged 3–5 years (0.98; 95% CI: 0.93–1.04), 6–17 years (1.02; 95% CI: 0.97–1.08), 18–49 years (1.02; 95% CI:0.98–1.05), 50–64 years (1.07; 95% CI: 1.04–1.11), ≥65 years (1.05; 95% CI:1.02–1.08). The PCV13 infant immunization program is temporally associated with a reduction in CAP incidence in vaccine target age group. However, no significant decrease in CAP incidence in other age groups warrants further study of the etiology of CAP to develop and implement effective prevention programs.
    Schlagwörter Streptococcus pneumoniae ; etiology ; immunization ; morbidity ; mortality ; pneumonia ; regression analysis ; vaccines ; British Columbia
    Sprache Englisch
    Erscheinungsverlauf 2022-0211
    Umfang p. 1047-1053.
    Erscheinungsort Elsevier Ltd
    Dokumenttyp Artikel
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2021.12.065
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  4. Artikel: Epidemiological analysis of the emergence and disappearance of the SARS-CoV-2 Kappa variant within a region of British Columbia, Canada.

    Ghafari, Cher / Benusic, Michael / Prystajecky, Natalie / Sbihi, Hind / Kamelian, Kimia / Hoang, Linda

    Canada communicable disease report = Releve des maladies transmissibles au Canada

    2022  Band 48, Heft 1, Seite(n) 22–26

    Abstract: Background: The Kappa variant is designated as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of interest (VOI). We identified 195 Kappa variant cases in a region of British Columbia, Canada-the largest published cluster in North ...

    Abstract Background: The Kappa variant is designated as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of interest (VOI). We identified 195 Kappa variant cases in a region of British Columbia, Canada-the largest published cluster in North America.
    Objectives: To describe the epidemiology of the Kappa variant in relation to other circulating SARS-CoV-2 variants of concern (VOC) in the region to determine if the epidemiology of the Kappa variant supports a VOI or VOC status.
    Methods: Clinical specimens testing positive for SARS-CoV-2 collected between March 10 and May 2, 2021, were screened for the detection of known circulating VOCs; approximately 50% of specimens were subsequently selected for whole genome sequencing (WGS). Epidemiological analysis was performed comparing the characteristics of Kappa cases to the main circulating variants in the region (Alpha and Gamma) and to non-VOC/VOI cases.
    Results: A total of 2,079 coronavirus disease 2019 (COVID-19) cases were reported in the region during the study period, of which 54% were selected for WGS. The 1,131 sequenced cases were categorized into Kappa, Alpha, Gamma and non-VOC/VOI. While Alpha and Gamma cases were found to have a significantly higher attack rate among household contacts compared to non-VOI/VOC cases, Kappa was not.
    Conclusion: Epidemiological analysis supports the designation of Kappa as a VOI and not a VOC. The Alpha and Gamma variants were found to be more transmissible, explaining their subsequent dominance in the region and the rapid disappearance of the Kappa variant. Variant surveillance strategies should focus on both detection of established VOCs and detection of potential new VOCs.
    Sprache Englisch
    Erscheinungsdatum 2022-01-26
    Erscheinungsland Canada
    Dokumenttyp Journal Article
    ZDB-ID 1146585-2
    ISSN 1188-4169
    ISSN 1188-4169
    DOI 10.14745/ccdr.v48i01a04
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.

    Vadlamudi, Nirma K / Patrick, David M / Rose, Caren / Sadatsafavi, Mohsen / Hoang, Linda / Marra, Fawziah

    Vaccine

    2022  Band 40, Heft 7, Seite(n) 1047–1053

    Abstract: Background: Pneumonia is a leading cause of morbidity and mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on community-acquired pneumonia (CAP) rates eight years after the vaccine was introduced in ... ...

    Abstract Background: Pneumonia is a leading cause of morbidity and mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on community-acquired pneumonia (CAP) rates eight years after the vaccine was introduced in the infant immunization program.
    Methods: Using diagnostic codes from administrative databases, we calculated the overall and age-specific CAP incidence per month (2000-2018). Changes in the CAP incidence before and after the PCV13 vaccine program introduction were evaluated using negative binomial regression model adjusting for 7-valent pneumococcal conjugate vaccine program.
    Results: The PCV13 vaccine infant immunization program was associated with declining CAP incidence among children aged 0-2 years (adjusted Incidence Rate Ratio (aIRR): 0.91; 95% CI: 0.87-0.96). Overall CAP incidence did not decrease in those aged 3-5 years (0.98; 95% CI: 0.93-1.04), 6-17 years (1.02; 95% CI: 0.97-1.08), 18-49 years (1.02; 95% CI:0.98-1.05), 50-64 years (1.07; 95% CI: 1.04-1.11), ≥65 years (1.05; 95% CI:1.02-1.08).
    Conclusions: The PCV13 infant immunization program is temporally associated with a reduction in CAP incidence in vaccine target age group. However, no significant decrease in CAP incidence in other age groups warrants further study of the etiology of CAP to develop and implement effective prevention programs.
    Mesh-Begriff(e) British Columbia/epidemiology ; Child ; Child, Preschool ; Community-Acquired Infections/epidemiology ; Community-Acquired Infections/prevention & control ; Humans ; Incidence ; Infant ; Infant, Newborn ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines ; Pneumonia, Pneumococcal/prevention & control ; Vaccines, Conjugate/therapeutic use
    Chemische Substanzen 13-valent pneumococcal vaccine ; Pneumococcal Vaccines ; Vaccines, Conjugate
    Sprache Englisch
    Erscheinungsdatum 2022-01-07
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2021.12.065
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study.

    Vadlamudi, Nirma Khatri / Sadatsafavi, Mohsen / Patrick, David M / Rose, Caren / Hoang, Linda / Marra, Fawziah

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

    2022  Band 25, Heft 9, Seite(n) 1510–1519

    Abstract: Objectives: Invasive pneumococcal disease (IPD) and a variety of clinical syndromes caused by pneumococci, such as acute otitis media (AOM), acute sinusitis (AS), and community-acquired pneumonia (CAP), cause a substantial burden on healthcare systems. ... ...

    Abstract Objectives: Invasive pneumococcal disease (IPD) and a variety of clinical syndromes caused by pneumococci, such as acute otitis media (AOM), acute sinusitis (AS), and community-acquired pneumonia (CAP), cause a substantial burden on healthcare systems. Few studies have explored the short-term financial burden of pneumococcal disease after the 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the infant immunization programs. This population-based study evaluated changes in costs associated with healthcare utilization for pneumococcal disease after the PCV13 introduction in the infant immunization program in British Columbia, Canada.
    Methods: Individuals with pneumococcal disease were identified using provincial administrative data for the 2000 to 2018 period. Total direct healthcare costs were determined using case-mix methodology for hospitalization and fee-for-service codes for outpatient visits and medications dispensed. Costs were adjusted to 2018 Canadian dollars. Changes in the annual healthcare costs were evaluated across vaccine eras (pre-PCV13, 2000-2010; PCV13, 2011-2018) using generalized linear models, adjusting for the 7-valent pneumococcal conjugate vaccine program (2004-2010).
    Results: During the 19-year study period, pneumococcal disease resulted in 6.3 million cases among 85 million total patient-years, resulting in total healthcare costs of $7.9 billion. More than 6.2 million cases were treated in outpatient setting, costing $0.65 billion (8% of total costs associated with pneumococcal disease treatment), whereas 370 000 hospitalized cases were 3% of all cases, which accrued $7.25 billion (92% of total costs) in costs. Healthcare costs for all studied infections nearly doubled over the study period from $248 million in 2000 to $476 million in 2018 (P = .003). In contrast, there were large declines in total annual costs in the PCV13 era for IPD (adjusted relative rate (aRR) 0.73; 95% confidence interval [CI] 0.56-0.95; P = .032), AOM (aRR 0.70; 95% CI 0.59-0.83; P = .001), and AS (aRR 0.68; 95% CI 0.54-0.85; P = .004) compared with the pre-PCV13 era. Total costs increased marginally in the PCV13 era for all-cause CAP (aRR 1.04; 95% CI 0.94-1.15; P = .484).
    Conclusions: This study confirms a temporal association in declining economic burden for IPD, AOM, and AS after the PCV13 introduction. Nevertheless, the total economic burden continues to be high in the PCV13 era, mainly driven by increasing CAP costs.
    Mesh-Begriff(e) Acute Disease ; British Columbia/epidemiology ; Health Care Costs ; Humans ; Incidence ; Infant ; Otitis Media/epidemiology ; Otitis Media/prevention & control ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines ; Vaccination ; Vaccines, Conjugate/therapeutic use
    Chemische Substanzen Pneumococcal Vaccines ; Vaccines, Conjugate
    Sprache Englisch
    Erscheinungsdatum 2022-04-21
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1471745-1
    ISSN 1524-4733 ; 1098-3015
    ISSN (online) 1524-4733
    ISSN 1098-3015
    DOI 10.1016/j.jval.2022.03.017
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: The utility of SARS-CoV-2 genomic data for informative clustering under different epidemiological scenarios and sampling.

    Sobkowiak, Benjamin / Haghmaram, Pouya / Prystajecky, Natalie / Zlosnik, James E A / Tyson, John / Hoang, Linda M N / Colijn, Caroline

    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases

    2023  Band 113, Seite(n) 105484

    Abstract: Objectives: Clustering pathogen sequence data is a common practice in epidemiology to gain insights into the genetic diversity and evolutionary relationships among pathogens. We can find groups of cases with a shared transmission history and common ... ...

    Abstract Objectives: Clustering pathogen sequence data is a common practice in epidemiology to gain insights into the genetic diversity and evolutionary relationships among pathogens. We can find groups of cases with a shared transmission history and common origin, as well as identifying transmission hotspots. Motivated by the experience of clustering SARS-CoV-2 cases using whole genome sequence data during the COVID-19 pandemic to aid with public health investigation, we investigated how differences in epidemiology and sampling can influence the composition of clusters that are identified.
    Methods: We performed genomic clustering on simulated SARS-CoV-2 outbreaks produced with different transmission rates and levels of genomic diversity, along with varying the proportion of cases sampled.
    Results: In single outbreaks with a low transmission rate, decreasing the sampling fraction resulted in multiple, separate clusters being identified where intermediate cases in transmission chains are missed. Outbreaks simulated with a high transmission rate were more robust to changes in the sampling fraction and largely resulted in a single cluster that included all sampled outbreak cases. When considering multiple outbreaks in a sampled jurisdiction seeded by different introductions, low genomic diversity between introduced cases caused outbreaks to be merged into large clusters. If the transmission and sampling fraction, and diversity between introductions was low, a combination of the spurious break-up of outbreaks and the linking of closely related cases in different outbreaks resulted in clusters that may appear informative, but these did not reflect the true underlying population structure. Conversely, genomic clusters matched the true population structure when there was relatively high diversity between introductions and a high transmission rate.
    Conclusion: Differences in epidemiology and sampling can impact our ability to identify genomic clusters that describe the underlying population structure. These findings can help to guide recommendations for the use of pathogen clustering in public health investigations.
    Mesh-Begriff(e) Humans ; SARS-CoV-2/genetics ; COVID-19/epidemiology ; Pandemics ; Disease Outbreaks ; Genomics ; Cluster Analysis
    Sprache Englisch
    Erscheinungsdatum 2023-07-31
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2037068-4
    ISSN 1567-7257 ; 1567-1348
    ISSN (online) 1567-7257
    ISSN 1567-1348
    DOI 10.1016/j.meegid.2023.105484
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Evaluation of the Aptima BV and CV/TV assays compared to conventional laboratory based testing methods for the diagnosis of vaginitis.

    Caza, Mélissa / Charles, Marthe / Locher, Kerstin / Hoang, Linda / Tucker, Morgan / Mandy, Jeremy / Jewsbury, Heather / Wilmer, Amanda

    Diagnostic microbiology and infectious disease

    2023  Band 106, Heft 4, Seite(n) 115953

    Abstract: Purpose: Vaginitis is caused by bacterial vaginosis (BV), Candida vaginitis (CV) and Trichomonas vaginalis (TV). This retrospective study evaluates the performance of the Aptima CV/TV, and BV assays on the automated Panther system.: Methods: Two ... ...

    Abstract Purpose: Vaginitis is caused by bacterial vaginosis (BV), Candida vaginitis (CV) and Trichomonas vaginalis (TV). This retrospective study evaluates the performance of the Aptima CV/TV, and BV assays on the automated Panther system.
    Methods: Two hundred forty-two multitest swabs were tested on the CV/TV assay and 422 on the BV assay. Positive and negative percent agreement (PPA, NPA) of the Candida glabrata (CG), Candida species group (CSG), TV and BV targets were calculated using a modified gold standard, with review of Gram smear and the usage of the Allplex Vaginitis Screening Assay to resolve discrepancies.
    Results: The PPA and NPA were respectively 98.4% and 95.9% for BV, 100% and 95.4% for CSG, 100% and 99% for CG, and 100% and 100% for TV, and when compared to consensus results.
    Conclusion: The CV/TV and BV assays surpassed the acceptance criteria threshold of 95%, and proved to be an excellent alternative to conventional testing.
    Mesh-Begriff(e) Female ; Humans ; Vaginosis, Bacterial/diagnosis ; Vaginosis, Bacterial/microbiology ; Trichomonas vaginalis/genetics ; Trichomonas Vaginitis/diagnosis ; Trichomonas Vaginitis/microbiology ; Retrospective Studies ; Candidiasis, Vulvovaginal/diagnosis ; Candidiasis, Vulvovaginal/microbiology ; Candida ; Candida glabrata
    Sprache Englisch
    Erscheinungsdatum 2023-04-26
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 604920-5
    ISSN 1879-0070 ; 0732-8893
    ISSN (online) 1879-0070
    ISSN 0732-8893
    DOI 10.1016/j.diagmicrobio.2023.115953
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: The Resurgence of Lymphogranuloma Venereum: Changing Presentation of Lymphogranuloma Venereum in the Era of HIV Preexposure Prophylaxis, 2004 to 2022.

    Gupta, Amit K / Lyons, Brody / Hunter, Ian / Arnold, Barbra / Gilbert, Mark / Hoang, Linda / Malleson, Sarah / Ryan, Venessa / Romney, Marc G / Severini, Alberto / Wong, Jason / Grennan, Troy

    Sexually transmitted diseases

    2024  Band 51, Heft 4, Seite(n) 233–238

    Abstract: Background: Before the early 2000s, the sexually transmitted infection lymphogranuloma venereum (LGV) was rare in high-income countries. Initially, most cases in these countries were among symptomatic men who have sex with men (MSM) living with HIV. In ... ...

    Abstract Background: Before the early 2000s, the sexually transmitted infection lymphogranuloma venereum (LGV) was rare in high-income countries. Initially, most cases in these countries were among symptomatic men who have sex with men (MSM) living with HIV. In the context of widespread HIV preexposure prophylaxis (PrEP), LGV's epidemiology may be changing. We aimed to characterize the epidemiology and clinical presentation of LGV in the PrEP era.
    Methods: A retrospective chart review was performed on all LGV cases occurring between November 2004 to October 2022 in British Columbia (BC), Canada. Cases were stratified by having occurred before (2004-2017) or after widespread PrEP availability in BC (2018-2022). Annual rates and test positivity percentages were calculated. Bivariate logistic regression was performed to identify drivers of asymptomatic infection in the PrEP era.
    Results: Among 545 cases identified, 205 (37.6%) occurred pre-PrEP and 340 (62.4%) occurred during the PrEP era. Most cases were among MSM (97.2%). The estimated rate of LGV has doubled from 2018 to 2022, reaching 1535.2 cases per 100,000 PrEP users. Most PrEP-era cases were among HIV-negative individuals (65.3%), particularly those on PrEP (72.6%). Cases in the PrEP era were often asymptomatic compared with pre-PrEP (38.6% vs. 19.3%; P < 0.001). Users of PrEP were more likely to experience asymptomatic infection compared with HIV-negative PrEP nonusers (odds ratio, 2.07; 95% confidence interval, 1.07-3.99).
    Conclusions: In the context of increased asymptomatic testing, LGV may be increasing in BC. Most infections now occur among HIV-negative MSM. A high proportion of infections are asymptomatic.
    Mesh-Begriff(e) Male ; Humans ; Lymphogranuloma Venereum/epidemiology ; Homosexuality, Male ; Chlamydia trachomatis ; Retrospective Studies ; Asymptomatic Infections ; Sexual and Gender Minorities ; HIV Infections/epidemiology ; British Columbia ; Pre-Exposure Prophylaxis
    Sprache Englisch
    Erscheinungsdatum 2024-01-26
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 435191-5
    ISSN 1537-4521 ; 0148-5717
    ISSN (online) 1537-4521
    ISSN 0148-5717
    DOI 10.1097/OLQ.0000000000001944
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Utilization rates of enoxaparin and heparin in deep venous thrombosis prophylaxis after education and electronic order change at a single institution: a quality improvement study.

    Hoang, Linda / Islam, Shahidul / Hindenburg, Alexander

    Journal of thrombosis and thrombolysis

    2018  Band 46, Heft 4, Seite(n) 502–506

    Abstract: Despite advantages of low molecular weight heparin (LMWH), enoxaparin over heparin (UFH) for venous thromboembolism (VTE), a hospital's prescribing trends analysis showed use of each was about equal. In an attempt to increase LMWH over UFH use, ... ...

    Abstract Despite advantages of low molecular weight heparin (LMWH), enoxaparin over heparin (UFH) for venous thromboembolism (VTE), a hospital's prescribing trends analysis showed use of each was about equal. In an attempt to increase LMWH over UFH use, electronic medical record (EMR) changes for medical service patients and education via multidisciplinary grand rounds was provided to all services. This was a unique opportunity to study LMWH and UFH use pre and post interventions at our institution. Citrix Pharmacy data was extracted for 3 months pre and post intervention (August 2016-February 2017). Inclusion criteria were age > 18 and LMWH or UFH VTE prophylaxis. Exclusion criteria were one time or duplicate orders and VTE treatment doses. Primary endpoint was hospital services VTE use with focus on medicine service which had both interventions compared to single intervention among all other services. LMWH use increased from 51 to 57.3% (p < 0.001) and UFH use decreased from 49 to 42.7% (p < 0.001) for all services. For medicine service, LMWH use increased 52.5-59.6% (p < 0.001) and UFH use decreased 47.5-40.4% (p < 0.001). For other services, LMWH use increased 48.8-53.6% (p = 0.005) and UFH use decreased 51.2-46.4% (p = 0.005). EMR changes and prescribers' grand rounds education resulted in 7.1% increase of LMWH use for medicine and 4.8% increase for all other services. The net increase (95% CI) in LMWH use in medicine service is 2.3% (- 1.91%, 6.56%) compared to the other services p = 0.281. Future studies are needed to reassess the effects of continued education and outcome of interventions.
    Mesh-Begriff(e) Adult ; Aged ; Aged, 80 and over ; Drug Prescriptions ; Education, Medical ; Enoxaparin/therapeutic use ; Heparin/therapeutic use ; Humans ; Premedication/trends ; Premedication/utilization ; Quality Improvement ; Teaching Rounds ; Venous Thrombosis/drug therapy ; Young Adult
    Chemische Substanzen Enoxaparin ; Heparin (9005-49-6)
    Sprache Englisch
    Erscheinungsdatum 2018-06-13
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-018-1727-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang